HRTX Stock — Heron Therapeutics Inc.: Cash, EV, Pipeline

Share price

$0.31

Market cap

$58.8M

Cash

$42.7M

Enterprise value

$16.1M

Balance sheet

Cash	$42.7M
Debt	$0.0M
Net cash	$42.7M
Enterprise value	$16.1M
Basic shares	190.3M shares
Fully diluted shares	251.3M shares
Fully diluted market cap	$77.9M
Cash per share	$0.22

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading HRTX daily closes…

Loading price history…

Pipeline assets

ZYNRELEF

Approved · Active Modality: extended-release solution

Partnerships CrossLink Network (exclusive U.S. co-promoter for ZYNRELEF, January 2024)

Indications

Postsurgical analgesia up to 72 hours after soft tissue and orthopedic surgical procedures (Approved)

Status note Bupivacaine and meloxicam extended-release solution; FDA approved May 2021 with indication expansions December 2021 and January 2024. CMS approved a new permanent J-code effective October 1, 2025.

APONVIE

Approved · Active Modality: injectable emulsion

Target NK1 receptor (substance P/neurokinin-1)

Indications

Postoperative nausea and vomiting (PONV) in adults (Approved)

Status note IV aprepitant; FDA approved September 2022, U.S. commercial launch March 2023. CMS approved a new permanent J-code effective April 1, 2026.

CINVANTI

Approved · Active Modality: injectable emulsion

Target NK1 receptor (substance P/neurokinin-1)

Indications

Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) (Approved)

Status note IV aprepitant; FDA approved November 2017, U.S. commercial launch January 2018. Subject to multiple Paragraph IV generic challenges (Mylan, Fresenius Kabi, Azurity/Slayback, Baxter, Long Grove).

SUSTOL

Approved · Active Modality: extended-release injection (Biochronomer technology)

Target 5-HT3 receptor

Indications

Prevention of acute and delayed nausea and vomiting with MEC and AC chemotherapy regimens (Approved)

Status note Granisetron extended-release injection; FDA approved August 2016, U.S. commercial launch October 2016. Company stated it would notify FDA if it decides to recommence commercial marketing and sale.

Per-asset detail extracted from the 10-Q filed 2026-08-10. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07639723	Not disclosed	Not yet recruiting	Collaborator	Endeavor Health	—	PONV	—

Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Endeavor Health on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
OrbiMed Advisors	0	-9,816,940	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

HRTX — Heron Therapeutics Inc.

Balance sheet

Price history

Pipeline assets

Active clinical trials

Institutional holders